Patient education materials
Novo Nordisk believes in supporting patients with resources to help them better understand bleeding disorders. These educational materials are available to download, share with patients, or order for your office.
Patient education materials
Novo Nordisk believes in supporting patients with resources to help them better understand hemophilia and rare bleeding disorders. These educational materials are available to download, share with patients, or order for your office.
Bob has hemophilia A with an inhibitor
Materials available through your Novo Nordisk Representative
The following items are available by contacting your representative:
Demonstration Kit
This kit demonstrates the compact storage size and portability of NovoSeven® RT, and helps you show patients how quick it is to reconstitute a dose of NovoSeven® RT.
Patient Starter Kit
Patients can practice mixing a dose before they start treatment. This kit includes a sample device, bilingual (English/Spanish) infusion mat, sample kit with test product, introductory brochure, and web key that launches an instructional reconstitution video. The kit comes in a zippered carrying case.
Ready-to-Travel Case
This portable, reusable travel case makes it possible to store supplies at home or while traveling.
To request a Demonstration Kit, Patient Starter Kit or Ready-to-Travel Case, please contact your representative.
Patient advocacy groups.
Hemophilia Federation of America (HFA)
Connecting people affected by bleeding disorders to others in their community, while advocating for the development of safe, affordable treatment options. Get more info at http://www.hemophiliafed.org.
National Hemophilia Foundation (NHF)
The largest nonprofit organization dedicated to education, advocacy, and research of inheritable bleeding disorders. Direct patients to find resources at https://www.hemophilia.org.
World Federation of Hemophilia (WFH)
Committed to improving and sustaining excellent care for people with bleeding disorders across the world. Help patients learn more about the WFH by sending them to https://www.wfh.org.
Product Support for patients.
Find resources and education for health care professionals.
Find the dose for your patients.*
*As a reminder, for US health care professionals only.
Selected Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
Indications and Usage
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:
- Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
- Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia
Important Safety Information
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
- Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
- Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
- Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis
Adverse Reactions
- The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia
Drug Interactions
- Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII
Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.